In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 271 to 280 of 294

Sort by

Guidance programme: Technology appraisal guidance`Remove $Guidance programme: Technology appraisal guidance filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]	Technology appraisal guidance	2 December 2026
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557]	Technology appraisal guidance	TBC
Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]	Technology appraisal guidance	13 January 2027
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]	Technology appraisal guidance	TBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]	Technology appraisal guidance	TBC
Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]	Technology appraisal guidance	TBC
Upadacitinib for treating giant cell arteritis [ID6299]	Technology appraisal guidance	14 October 2026
Vamikibart for treating uveitic macular oedema ID6671	Technology appraisal guidance	TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]	Technology appraisal guidance	TBC
Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468]	Technology appraisal guidance	TBC

Results per page

10
25
50
All